Aveanna Healthcare (NASDAQ:AVAH) Issues Earnings Results, Beats Expectations By $0.05 EPS

Aveanna Healthcare (NASDAQ:AVAH) posted its earnings results on Thursday. The company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.17 by $0.05, FiscalAI reports. Aveanna Healthcare had a return on equity of 124.68% and a net margin of 10.37%.The firm had revenue of $670.48 million for the quarter, compared to the consensus estimate of $638.61 million.

Here are the key takeaways from Aveanna Healthcare’s conference call:

• Q2 revenue rose 13.7% to $670.5 million, while adjusted EBITDA increased 8% to $95.4 million, with year-over-year growth across all three operating segments.
• Aveanna raised 2026 guidance to revenue above $2.68 billion and adjusted EBITDA above $365 million, attributing the increase to core organic performance rather than the recently acquired Family First business.
• The company reported progress on reimbursement and payer initiatives, including seven state rate increases, 37 Private Duty Services preferred payer agreements, and a significant California pediatric nursing rate increase scheduled for January 2027. Aveanna also lifted its long-term organic growth targets for Private Duty Services to 5%–6% and Home Health and Hospice to 8%–10%.
• Management expects gross-margin percentages to remain broadly stable because reimbursement gains will largely be passed through to caregiver wages; it plans to raise California wages ahead of the January 2027 rate increase, creating potential near-term margin pressure. The company also remains highly leveraged, with approximately $1.48 billion of variable-rate debt, despite targeting leverage below 3x over time.

Aveanna Healthcare Stock Up 18.4%

AVAH traded up $1.67 during trading on Thursday, hitting $10.71. 4,781,488 shares of the company’s stock traded hands, compared to its average volume of 1,615,697. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of 9.00, a PEG ratio of 0.89 and a beta of 1.90. The company’s 50 day simple moving average is $8.77 and its two-hundred day simple moving average is $7.71. Aveanna Healthcare has a 12-month low of $5.93 and a 12-month high of $10.91. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 5.35.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Stephens raised Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $10.00 to $11.00 in a research note on Friday, May 15th. Weiss Ratings reissued a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Thursday, July 2nd. Barclays increased their price target on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Truist Financial upped their price objective on shares of Aveanna Healthcare from $9.00 to $11.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Finally, Royal Bank Of Canada raised shares of Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.78.

Insiders Place Their Bets

In other news, major shareholder Robert M. Williams, Jr. sold 7,000,000 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $6.24, for a total transaction of $43,680,000.00. Following the transaction, the insider directly owned 252,899 shares of the company’s stock, valued at $1,578,089.76. This represents a 96.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Patrick A. Cunningham sold 125,000 shares of the stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $7.59, for a total value of $948,750.00. Following the sale, the insider directly owned 212,755 shares in the company, valued at $1,614,810.45. This trade represents a 37.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 31,305,664 shares of company stock worth $215,555,910 over the last three months. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd raised its holdings in Aveanna Healthcare by 8.9% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 14,149 shares of the company’s stock worth $126,000 after purchasing an additional 1,151 shares during the period. Barclays PLC lifted its position in Aveanna Healthcare by 0.8% during the third quarter. Barclays PLC now owns 179,359 shares of the company’s stock valued at $1,591,000 after purchasing an additional 1,366 shares in the last quarter. Franklin Resources Inc. grew its holdings in Aveanna Healthcare by 4.5% during the third quarter. Franklin Resources Inc. now owns 35,630 shares of the company’s stock valued at $316,000 after purchasing an additional 1,528 shares during the period. Intech Investment Management LLC grew its holdings in Aveanna Healthcare by 9.8% during the fourth quarter. Intech Investment Management LLC now owns 19,483 shares of the company’s stock valued at $159,000 after purchasing an additional 1,739 shares during the period. Finally, Prelude Capital Management LLC increased its position in Aveanna Healthcare by 16.1% in the third quarter. Prelude Capital Management LLC now owns 31,621 shares of the company’s stock worth $280,000 after buying an additional 4,385 shares in the last quarter. Institutional investors own 87.96% of the company’s stock.

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Q2 results exceeded expectations. Aveanna reported adjusted earnings of $0.22 per share, above the $0.17 analyst consensus and up from $0.18 a year earlier. Revenue rose 13.7% year over year to $670.5 million, surpassing estimates of approximately $638.6 million. Aveanna Healthcare Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Profitability improved materially. Second-quarter net income increased to $40.3 million from $27.0 million in the prior-year period, while adjusted EBITDA grew 8.0% to $95.4 million. The company reported a 10.37% net margin and 124.68% return on equity. Aveanna Healthcare Announces Second Quarter Financial Results and Revised 2026 Guidance
• Positive Sentiment: Full-year guidance was raised. Aveanna increased 2026 revenue guidance to more than $2.68 billion, from $2.63 billion to $2.65 billion previously. Adjusted EBITDA guidance was raised to above $365 million, versus the prior range of $338 million to $342 million. The upgrades suggest management sees continued momentum in its home-care operations. Aveanna Healthcare Revised 2026 Guidance
• Neutral Sentiment: Separate coverage is examining the quarter’s operating metrics against Wall Street estimates and year-ago results. The company’s FY 2026 EPS guidance entry did not provide a usable figure, limiting the earnings outlook to revenue and adjusted EBITDA. Aveanna Q2 Earnings Key Metrics
• Neutral Sentiment: Reported short interest was listed at zero shares, offering no meaningful indication of bearish positioning or potential short-covering demand.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.